Oric Pharmaceuticals
ORIC
122 hedge funds and large institutions have $715M invested in Oric Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 39 reducing their positions, and 13 closing their positions.
1,838% more call options, than puts
Call options by funds: $155K | Put options by funds: $8K
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
50% more capital invested
Capital invested by funds: $478M → $715M (+$237M)
8% more funds holding
Funds holding: 113 → 122 (+9)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 39
1.36% less ownership
Funds ownership: 100.34% → 98.98% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$14.3M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$11.2M |
| 3 |
SCM
Superstring Capital Management
New York
|
+$9.39M |
| 4 |
BlackRock
New York
|
+$2.68M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$2.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.35M |
| 2 |
Millennium Management
New York
|
-$4.83M |
| 3 |
State Street
Boston,
Massachusetts
|
-$3.14M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.03M |
| 5 |
O
OrbiMed
New York
|
-$2.03M |
ORIC Hedge Fund Activity: Q3 2024 in Review
122 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q3 2024, worth a combined $715M — up 50% from $478M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ORIC positions and 13 closed out — a net gain of 10 holders — while 39 added to existing stakes and 39 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $14.3M. The largest seller was Fidelity Investments, cutting an estimated $5.35M.
- 122 institutional investors held Oric Pharmaceuticals (ORIC) as of Q3 2024, up from 113 in Q2 2024.
- Funds reported $715M of Oric Pharmaceuticals stock for Q3 2024, up 50% quarter-over-quarter.
- 23 funds opened new Oric Pharmaceuticals positions in Q3 2024 and 13 closed out, a net change of +10 holders.
- The largest Oric Pharmaceuticals buyer in Q3 2024 was Avidity Partners Management, an estimated $14.3M added.
- The largest Oric Pharmaceuticals seller in Q3 2024 was Fidelity Investments, an estimated $5.35M sold.
Based on aggregated 13F filings for Q3 2024.